We have developed a powerful technology to discover and develop therapeutic monoclonal antibodies. Our Kymouse™ technology is capable of rapidly generating an exceptionally broad diversity and quality of fully human antibodies against challenging disease targets. The precision engineering of our Kymouse™ platform has translated into exceptional performance. The platform generates very high affinity, candidate-quality molecules without the need for further lead optimisation.
Founded in 2009, Kymab raised $30m of equity financing in 2010 from The Wellcome Trust Investment Division to enable the development of the Kymouse™ platform and create a portfolio of therapeutic assets. In 2014, The Bill and Melinda Gates Foundation together with The Wellcome Trust invested a further $40 million in Kymab. This enables our mission to advance our pipeline of first-in-class therapeutics and embark on vaccine development in areas of high unmet medical need.
We provide extraordinary career opportunities for talented individuals, who will have the opportunity to work with highly experienced leaders in science and business with proven track records in building successful biotechnology companies and getting product through the clinic and on to the market. Our success depends on the quality, experience and ambition of the individuals that join our team.